Last $118.45 USD
Change Today +3.96 / 3.46%
Volume 2.5M
SLXP On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (SLXP) Snapshot

Open
$116.00
Previous Close
$114.49
Day High
$121.51
Day Low
$112.73
52 Week High
09/24/14 - $172.98
52 Week Low
12/19/13 - $84.10
Market Cap
7.5B
Average Volume 10 Days
1.7M
EPS TTM
$0.91
Shares Outstanding
63.7M
EX-Date
--
P/E TM
129.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for SALIX PHARMACEUTICALS LTD (SLXP)

salix pharmaceuticals ltd (SLXP) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (SLXP) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

555 Employees
Last Reported Date: 02/28/14
Founded in 1989

salix pharmaceuticals ltd (SLXP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $867.5K
Chief Development Officer, Chief Medical Offi...
Total Annual Compensation: $466.4K
Executive Vice President of Business Developm...
Total Annual Compensation: $437.0K
Compensation as of Fiscal Year 2013.

salix pharmaceuticals ltd (SLXP) Key Developments

Salix Pharmaceuticals Ltd. Provides Earnings Guidance for the Year 2015 and 2016

Salix Pharmaceuticals Ltd. provided earnings Guidance for 2015 and 2016. For the year 2015, the company expects, total net product revenue of between approximately $1.25 billion and $1.35 billion. Salix believes total net product revenue would increase by approximately $400 million to $450 million if the company sold its products based on prescription demand in 2015. Gross margins of approximately 80%. Gross-to-net adjustments of between approximately 30% and 32%. EBITDA of between approximately $360 million and $440 million. Salix believes EBITDA would increase by approximately $315 million to $355 million if the company sold its products based on prescription demand in 2015, which represents the net product revenue increase discussed above reduced by approximately 20% for cost of goods sold. Cash income tax rate of approximately 3%. Earnings per share of between approximately $3.10 and $4.10 and fully diluted shares of 77 million. GAAP net loss is expected to be $37.0 million. EBITDA of $402 million. Non-GAAP net income to be $277 million or $3.59 per diluted share. For the year 2016, the company expects, total net product revenue of between approximately $1.9 billion and $2.0 billion. Gross margins of approximately 80%. Gross-to-net adjustments of between approximately 28% and 30%. EBITDA of between approximately $865 million and $945 million. Cash income tax rate of approximately 14%. Earnings per share of between approximately $8.50 and $9.50 and fully diluted shares of 77 million. GAAP net income is expected to be $274 million. EBITDA of $907 million. Non-GAAP net income to be $691 million or $8.98 per diluted share.

Pomerantz LLP Announces the Filing of a Class Action Lawsuit against Salix Pharmaceuticals Ltd

Pomerantz LLP has filed a class action lawsuit against Salix Pharmaceuticals Ltd. and certain of its officers. The class action, filed in United States District Court, Southern District of New York, is on behalf of a class consisting of all persons or entities who purchased Salix securities between August 7, 2014 and November 6, 2014, inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the company's business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: the company overstated demand for Salix's drugs; the company understated wholesaler inventory levels for Salix's products; Salix's internal controls over financial reporting was ineffective; and as a result of the foregoing, Salix's public statements were materially false and misleading at all relevant times. On November 6, 2014, after the close of trading, the company issued a press release announcing the resignation of its Chief Financial Officer, Adam C. Derbyshire. Minutes after issuing the press release, the company issued an earnings release and filed a Form 8-K announcing its financial and operating results for the third quarter ending September 30, 2014 and hosted an earnings conference call with investors and analysts. The company also disappointed investors by reporting earnings and revenues for the third quarter and providing guidance for fourth quarter earnings and revenues, below the projection of analysts. According to the release, the company had revenue of $355 million in the third quarter, up 49% from the same period last year, and reported earnings per share of $1.53. This was below the consensus among Wall Street analysts, which had expected revenue of $392 million and earnings per share of $1.55. In the earnings release, the company also provided guidance for the fourth quarter, forecasting that earnings per share will be $1.16, on revenue of $325 million, compared with the average projection of analysts of $1.95 per share on revenue of $436 million. As a result of this news, shares of Salix fell $47.08 per share, or 33.98%, to close at $91.47 per share on heavy trading volume, on November 7, 2014.

Salix Pharmaceuticals Ltd. and Pharming Group NV Announce Launch of Hereditary Angioedema Drug in Us

Salix Pharmaceuticals Ltd. and Pharming Group NV announce the launch of RUCONEST 50IU/kg in the US for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema, or HAE. Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. RUCONEST is available by prescription across the US through RUCONEST SOLUTIONS and comes with comprehensive patient support services. RUCONEST is manufactured by Pharming Group NV in the Netherlands. Salix has licensed exclusive rights from Pharming to commercialize RUCONEST in North America and market RUCONEST for the treatment of acute HAE attack symptoms.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLXP:US $118.45 USD +3.96

SLXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $57.68 USD +1.77
Cubist Pharmaceuticals Inc $97.77 USD -0.03
Jazz Pharmaceuticals PLC $169.88 USD +3.48
Lupin Ltd 1,426 INR +33.00
Recordati SpA €13.04 EUR +0.12
View Industry Companies
 

Industry Analysis

SLXP

Industry Average

Valuation SLXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.8x
Price/Book 12.4x
Price/Cash Flow 66.2x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.